These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 2385731)

  • 1. Giant invasive prolactinoma: a case report and review of nine further cases.
    Davis JR; Sheppard MC; Heath DA
    Q J Med; 1990 Mar; 74(275):227-38. PubMed ID: 2385731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of extensively invasive (giant) prolactinomas with bromocriptine.
    Grebe SK; Delahunt JW; Feek CM
    N Z Med J; 1992 Apr; 105(931):129-31. PubMed ID: 1560924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Invasive giant prolactinoma].
    Domínguez Ugidos LJ; Martínez Subías J; Urpegui García A; Sancho Serrano E; Alfonso Collado JI; Vallés Varela H
    Acta Otorrinolaringol Esp; 1998 Mar; 49(2):156-8. PubMed ID: 9650316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502.
    Glaser B; Nesher Y; Barziliai S
    J Reprod Med; 1994 Jun; 39(6):449-54. PubMed ID: 7932398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.
    Delgrange E; Sassolas G; Perrin G; Jan M; Trouillas J
    Acta Neurochir (Wien); 2005 Jul; 147(7):751-7; discussion 757-8. PubMed ID: 15971099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of prolactinoma with a new dopamine agonist].
    Svoboda T; Luger A; Knosp E; Geyer G
    Dtsch Med Wochenschr; 1991 Aug; 116(33):1224-7. PubMed ID: 1678695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endocrine function, psychiatric and clinical consequences in patients with macroprolactinomas after long-term treatment with the new non-ergot dopamine agonist CV205-502.
    Barnett PS; Palazidou E; Miell JP; Coskeran PB; Butler J; Dawson JM; Maccabe J; McGregor AM
    Q J Med; 1991 Nov; 81(295):891-906. PubMed ID: 1687293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the new dopaminergic agonist CV 205-502 on plasma prolactin levels and tumour size in bromocriptine-resistant prolactinomas.
    Duranteau L; Chanson P; Lavoinne A; Horlait S; Lubetzki J; Kuhn JM
    Clin Endocrinol (Oxf); 1991 Jan; 34(1):25-9. PubMed ID: 1672268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Results of treatment for male prolactinomas].
    Iwai Y; Yamanaka K; Ishiguro T; Morikawa T; Matsuzaka Y; Komiyama M; Yasui T
    No Shinkei Geka; 2002 Dec; 30(12):1285-92. PubMed ID: 12491580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prolactinoma in a child showing high MIB-1 labeling index: a case report].
    Akamine S; Miyamoto T; Sugiura Y; Takehara S; Hiramatsu H; Nishizawa S; Yokota N
    No Shinkei Geka; 2000 Jun; 28(6):547-53. PubMed ID: 10875113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aldosterone response to metoclopramide in patients with prolactinoma: effect of short-term bromocriptine treatment.
    Zacharieva S; Stoeva I; Andreeva M; Kalinov K; Matrozov P; Andonova K
    Methods Find Exp Clin Pharmacol; 1996 Nov; 18(9):593-7. PubMed ID: 9010834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A giant prolactinoma and the effect of chronic bromocriptine therapy on basal and TRH-stimulated serum prolactin levels.
    Barrera CM; Ruiz AE; Banks WA
    Horm Res; 1991; 35(3-4):167-9. PubMed ID: 1806471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of therapy and pregnancy on hyperprolactemia caused by a pituitary adenoma. A clinical case].
    Pasinetti E; Schivardi MR; Falsetti L; Gastaldi A
    Minerva Ginecol; 1989 Mar; 41(3):157-60. PubMed ID: 2666885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Withdrawal of bromocriptine after long-term therapy for macroprolactinomas; effect on plasma prolactin and tumour size.
    van 't Verlaat JW; Croughs RJ
    Clin Endocrinol (Oxf); 1991 Mar; 34(3):175-8. PubMed ID: 2036725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Additional antitumoral effects of bromocriptine and radiotherapy in patients with prolactinomas or acromegaly.
    Coculescu M; Alessandrescu D; Stoica T; Simionescu N; Dimitriu V; Oprescu M; Chelmu S; Urba-Navicius V; Isbăşoiu O
    Endocrinologie; 1980; 18(4):277-88. PubMed ID: 7209360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gender-related differences in prolactin secretion in pituitary prolactinomas.
    Nishioka H; Haraoka J; Akada K; Azuma S
    Neuroradiology; 2002 May; 44(5):407-10. PubMed ID: 12012125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Macroprolactinoma resistant to bromocriptine].
    López-Espinosa E; Ayala AR; Grimaldo J; Kunhardt J; Villanueva C
    Arch Invest Med (Mex); 1989; 20(1):1-8. PubMed ID: 2669670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Light microscopical morphometry of prolactin secreting adenomas under treatment with dopamine agonists.
    Hamester U; Saeger W; Lüdecke DK
    Histol Histopathol; 1987 Apr; 2(2):135-42. PubMed ID: 2980713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic study of 123 cases of prolactin-secreting pituitary adenomas with special reference to multihormone production and clonality of the adenomas.
    Ma W; Ikeda H; Yoshimoto T
    Cancer; 2002 Jul; 95(2):258-66. PubMed ID: 12124824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abnormal LH pulsatility in women with hyperprolactinaemic amenorrhoea normalizes after bromocriptine treatment: deconvolution-based assessment.
    Sartorio A; Pizzocaro A; Liberati D; De Nicolao G; Veldhuis JD; Faglia G
    Clin Endocrinol (Oxf); 2000 Jun; 52(6):703-12. PubMed ID: 10848874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.